Zevra Therapeutics (ZVRA) Aktievy
Zevra Therapeutics, Inc, ett bolag i kommersiell fas, fokuserar på att tillgodose icke tillgodosedda behov för behandling av sällsynta sjukdomar i USA. Mer information
| Snöflinga Score | |
|---|---|
| Värdering | 5/6 |
| Framtida tillväxt | 5/6 |
| Tidigare resultat | 3/6 |
| Finansiell hälsa | 6/6 |
| Utdelningar | 0/6 |
Belöningar
Riskanalys
ZVRA Community Fair Values
Create NarrativeSee what 75 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
Zevra Therapeutics, Inc. Konkurrenter
Prishistorik och prestanda
| Historiska aktiekurser | |
|---|---|
| Aktuell aktiekurs | US$11.48 |
| 52 veckors högsta | US$15.04 |
| 52 veckors lägsta | US$7.16 |
| Beta | 0.92 |
| 1 månads förändring | -14.01% |
| 3 månaders förändring | 3.89% |
| 1 års förändring | -1.88% |
| 3 års förändring | 112.59% |
| 5 års förändring | 28.84% |
| Förändring sedan börsintroduktionen | -93.59% |
Senaste nyheter och uppdateringar
Recent updates
Uppdatering av berättelse • Jul 24
CHMP/EMA Refusal & Financial Risk Analysis
Zevra Therapeutics received a negative opinion (refusal) from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) regarding the Marketing Authorization Application (MAA) for Meplyffa (arimoclomol) for the treatment of Niemann-Pick disease type C (NPC). Following the announcement, the stock reacted with an immediate ~30% decline, dropping to the $8.56 level.Seeking Alpha • Jul 23
Zevra Therapeutics: Worthy Of An Initial Holding
Summary Zevra Therapeutics surged after Miplyffa’s patent was listed in the FDA Orange Book, granting exclusivity through 2041. ZVRA achieved FY25 net sales of $87.4M, moved into profitability, retired all debt, and now holds $236.8M in cash and investments. The pipeline is focused on late-stage celiprolol for VEDS, with no clinical competition and FDA Orphan and Breakthrough Therapy designations. Trading at ~9x FY27E EPS (net of cash), ZVRA offers expansion potential, a clean balance sheet, and possible takeout appeal—supporting a small purchase. Read the full article on Seeking Alpha
Ny berättelse • Jul 20
Zevra Therapeutics: Galloping Through a Green Safari
From Prodrugs to a Rare Disease Powerhouse Zevra Therapeutics wasn’t always a rare disease contender. Originally known as KemPharm , the company spent years focused on prodrug technology for ADHD and pain management.
Uppdatering av berättelse • Jul 02
ZVRA: Extended Patent Exclusivity May Support Longer NPC Revenue Runway
The analyst price target for Zevra Therapeutics has shifted from $18 to $21, with analysts pointing to extended Miplyffa patent exclusivity and updated cash flow assumptions as key drivers of their higher valuation work. Analyst Commentary on Zevra Therapeutics Recent Street research on Zevra Therapeutics has focused on how extended Miplyffa intellectual property coverage could affect long term cash flow modeling, with several firms updating their price targets and assumptions around the duration of exclusivity.
Uppdatering av berättelse • Jun 18
ZVRA: Extended Rare Disease IP Runway Will Drive Future Upside Potential
Analysts have raised the fair value estimate for Zevra Therapeutics to $35 from $26, aligning it with updated Street price targets in the $27 to $35 range, as they incorporate extended Miplyffa intellectual property protection and a higher future P/E assumption into their models. Analyst Commentary Recent research updates on Zevra Therapeutics cluster around one theme: bullish analysts are reassessing the stock’s upside as they factor in longer intellectual property protection for Miplyffa and refine their cash flow models.
Ny berättelse • Jun 09
Discounted Exit Multiple Approach (DEM)
Disclaimer: This financial analysis is for informational purposes only and does not constitute investment advice. Zevra Therapeutics is a rare disease pharmaceutical company fundamentally driven by a single commercial product.Uppdatering av berättelse • Jun 03
ZVRA: NPC Diagnosis Expansion Will Drive Future Upside Potential
Analysts have raised their average price target for Zevra Therapeutics to $23 from $22, citing early Miplyffa adoption trends, positive views on potential expansion opportunities, and ongoing adjustments to growth, margin and P/E assumptions in their models. Analyst Commentary Bullish analysts are leaning into a constructive view on Zevra Therapeutics, framing the updated US$23 average price target as grounded in observable Miplyffa adoption trends and modeled upside from expansion opportunities.Uppdatering av berättelse • Apr 23
ZVRA: NPC Diagnosis Expansion And EU Decision Will Drive Future Upside Potential
Narrative Update: Zevra Therapeutics The updated analyst price target for Zevra Therapeutics is now $23, a $1 increase, as analysts point to the launch progress of Miplyffa, expectations for continued U.S. market penetration, and potential future catalysts including EU approval, patent term extension, and celiprolol development in VEDS. Analyst Commentary Bullish analysts are highlighting Zevra Therapeutics as a name where current valuation is closely linked to the rollout of Miplyffa and a set of identifiable potential catalysts.Uppdatering av berättelse • Apr 08
ZVRA: NPC Diagnosis Expansion Will Drive Future Upside Potential
Analysts have maintained Zevra Therapeutics' fair value estimate at $26.00, with slight tweaks to growth, margin, and future P/E assumptions. Recent Street research highlights a $23 price target, supported by views that current pricing reflects conservative Miplyffa adoption and potential upside from broader patient reach and future regulatory or pipeline milestones.Uppdatering av berättelse • Mar 24
ZVRA: Expanding NPC Diagnosis And EU Decision Will Drive Future Upside
Analysts have kept Zevra Therapeutics' fair value estimate steady at $26.00 while updating their assumptions on Miplyffa's launch trajectory and potential upside from EU approval, expanded U.S. adoption, and celiprolol optionality, which they note is reflected in Street price targets moving toward $23.00. Analyst Commentary Bullish analysts are framing Zevra's current share price as tied closely to conservative expectations for Miplyffa, largely anchored to the already diagnosed U.S. Niemann Pick type C population.Uppdatering av berättelse • Mar 10
ZVRA: Growing NPC Access And Data Will Support Long-Term Rare Disease Upside
Analysts have maintained their $26.00 price target for Zevra Therapeutics, citing updated assumptions that reflect slightly different estimates for revenue growth, profit margins, and future P/E, without materially changing their overall view of the stock's valuation. What's in the News Zevra Therapeutics appointed Justin Renz as Chief Financial Officer, effective March 9, 2026.Uppdatering av berättelse • Feb 24
ZVRA: Expanded Access And NPC Data Will Support Long-Term Rare Disease Upside
Analysts have kept their Zevra Therapeutics price target steady at $26.00. This points to largely unchanged fair value assumptions, even as they refine inputs such as revenue growth, profit margins and future P/E expectations.Uppdatering av berättelse • Feb 09
ZVRA: Expanded Access And NPC Data Will Support Long-Term Rare Disease Upside
Analysts have maintained their price target on Zevra Therapeutics at $26.00, citing only modest tweaks to assumptions around revenue growth, profit margins, the discount rate, and future P/E that did not materially change their overall view. What's in the News Zevra presented four posters at the 22nd Annual WORLDSymposium highlighting new data on MIPLYFFA (arimoclomol) for Niemann Pick Disease Type C.Uppdatering av berättelse • Jan 26
ZVRA: Expanded Access Deal Will Support Long-Term Rare Disease Upside
Narrative Update: Zevra Therapeutics Analyst Price Target The analyst price target for Zevra Therapeutics is now set at US$26.00. Analysts cite small adjustments to revenue growth assumptions, profit margin expectations, and future P/E estimates as key drivers for the updated view.Uppdatering av berättelse • Jan 11
ZVRA: Expanded Rare Disease Access Agreement Will Support Long-Term Upside
Analysts have maintained their price target for Zevra Therapeutics at US$26.00, citing only modest adjustments to assumptions around revenue growth, profit margins and future P/E. Taken together, these changes do not alter their overall view of the company’s valuation.Uppdatering av berättelse • Dec 26
ZVRA: Future Rare Disease Portfolio Will Support Long-Term Upside
Analysts have modestly increased their price target on Zevra Therapeutics to $26.00 per share, citing slightly stronger long term revenue growth and profit margin assumptions, alongside a marginally lower projected future price to earnings multiple. What's in the News Chief Financial Officer and Treasurer R.Uppdatering av berättelse • Dec 12
ZVRA: Future Rare Disease Approvals Will Drive Long-Term Upside
Analysts have reduced their price target on Zevra Therapeutics by 3.00 dollars to 26.00 dollars, citing expectations for slower revenue growth, slightly lower profit margins, and a modestly higher discount rate, partially offset by a lower anticipated future price to earnings multiple. What's in the News Chief Financial Officer and Treasurer R.Analysartikel • Nov 08
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Just Reported And Analysts Have Been Cutting Their Estimates
It's been a mediocre week for Zevra Therapeutics, Inc. ( NASDAQ:ZVRA ) shareholders, with the stock dropping 13% to...Analysartikel • Nov 03
Zevra Therapeutics (NASDAQ:ZVRA) Is Using Debt Safely
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analysartikel • Sep 08
What You Can Learn From Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) P/S After Its 26% Share Price Crash
Zevra Therapeutics, Inc. ( NASDAQ:ZVRA ) shares have had a horrible month, losing 26% after a relatively good period...Analysartikel • Jul 10
Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) 26% Jump Shows Its Popularity With Investors
Zevra Therapeutics, Inc. ( NASDAQ:ZVRA ) shares have continued their recent momentum with a 26% gain in the last month...Analysartikel • May 22
Revenues Tell The Story For Zevra Therapeutics, Inc. (NASDAQ:ZVRA) As Its Stock Soars 26%
Zevra Therapeutics, Inc. ( NASDAQ:ZVRA ) shareholders would be excited to see that the share price has had a great...
Ny berättelse • Apr 29
MIPLYFFA Launch Will Spark European Expansion In 2025
Successful MIPLYFFA launch and European expansion plans indicate potential revenue growth and stable streams through strong demand and patient engagement.Analysartikel • Mar 10
Investors Appear Satisfied With Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) Prospects
When close to half the companies in the Pharmaceuticals industry in the United States have price-to-sales ratios (or...Analysartikel • Nov 15
Here's What Analysts Are Forecasting For Zevra Therapeutics, Inc. (NASDAQ:ZVRA) After Its Third-Quarter Results
As you might know, Zevra Therapeutics, Inc. ( NASDAQ:ZVRA ) last week released its latest third-quarter, and things did...Analysartikel • Aug 30
Investors Appear Satisfied With Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) Prospects As Shares Rocket 34%
Zevra Therapeutics, Inc. ( NASDAQ:ZVRA ) shares have continued their recent momentum with a 34% gain in the last month...Aktieägarnas avkastning
| ZVRA | US Pharmaceuticals | US Marknad | |
|---|---|---|---|
| 7D | 14.2% | 3.2% | 2.7% |
| 1Y | -1.9% | 57.6% | 20.9% |
Avkastning vs industri: ZVRA presterade sämre än US Pharmaceuticals branschen som gav 57.6 % under det senaste året.
Avkastning vs Marknaden: ZVRA presterade sämre än US marknaden som gav 20.9 % under det senaste året.
Prisvolatilitet
| ZVRA volatility | |
|---|---|
| ZVRA Average Weekly Movement | 11.5% |
| Pharmaceuticals Industry Average Movement | 9.3% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.1% |
Stabil aktiekurs: ZVRA s aktiekurs har varit volatil under de senaste 3 månaderna jämfört med marknaden för US.
Volatilitet över tid: ZVRA s veckovolatilitet ( 11% ) har varit stabil under det senaste året, men är fortfarande högre än 75 % av US aktier.
Om företaget
| Grundad | Anställda | VD OCH KONCERNCHEF | Webbplats |
|---|---|---|---|
| 2006 | 61 | Neil McFarlane | www.zevra.com |
Zevra Therapeutics, Inc. är ett bolag i kommersiell fas som fokuserar på att tillgodose icke tillgodosedda behov för behandling av sällsynta sjukdomar i USA. Bolaget utvecklar sina produkter genom Ligand Activated Technology-plattformen. Bolagets ledande produktkandidat är KP1077, som består av KP1077IH, som genomgår klinisk fas 3-studie för behandling av idiopatisk hypersomni, och KP1077N, som genomgår klinisk fas 3-studie för behandling av narkolepsi.
Zevra Therapeutics, Inc. Sammanfattning av grunderna
| ZVRA grundläggande statistik | |
|---|---|
| Börsvärde | US$686.48m |
| Vinst(TTM) | US$57.25m |
| Intäkter(TTM) | US$136.07m |
11.9x
P/E-förhållande5.0x
P/S-förhållandeÄr ZVRA övervärderat?
Se Verkligt värde och värderingsanalysResultat & intäkter
| ZVRA resultaträkning (TTM) | |
|---|---|
| Intäkter | US$136.07m |
| Kostnad för intäkter | US$6.18m |
| Bruttovinst | US$129.89m |
| Övriga kostnader | US$72.64m |
| Intäkter | US$57.25m |
Senast redovisade vinst
Jun 30, 2026
Nästa vinstdatum
n/a
| Vinst per aktie (EPS) | 0.96 |
| Bruttomarginal | 95.46% |
| Nettovinstmarginal | 42.07% |
| Skuld/egenkapitalförhållande | 0% |
Hur har ZVRA utvecklats på lång sikt?
Se historisk utveckling och jämförelseFöretagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/08/10 23:06 |
| Aktiekurs vid dagens slut | 2026/08/10 00:00 |
| Intäkter | 2026/06/30 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som används för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och handledningar på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Zevra Therapeutics, Inc. bevakas av 17 analytiker. 9 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Kenneth Trbovich | Brean Capital Historical (Janney Montgomery) |
| Kambiz Yazdi | BTIG |
| Sumant Satchidanand Kulkarni | Canaccord Genuity |